Moderator: Manny Papadimitropoulos, MScPhm, PhD, Health Outcomes Scientific Leader Latin America, Eli Lilly and Company, Pickering, ON, Canada
Speakers: Jaime Calderon Herera, -, Project Manager, Virtual Hospital, Fundación Cardiovascular de Colombia, Bucaramanga, Santander, Colombia; Stephen Stefani, MD, Head of Oncology, Hospital do Câncer Mãe de Deus, Porto Alegre, Brazil; Martin Petrocco, -, Project Manager, Asociación Civil para el Enfermo de Psoriasis (AEPSO), Buenos Aires, Argentina
There is increasing recognition that HTAs involving evaluation of clinical and cost effectiveness are an incomplete assessment of value and that a broader evaluation is needed including patient and social aspects. Patients have unique knowledge about living with a disease and taking treatments that can help resolve uncertainties in HTA. Patients can be involved in HTA through rigorous forms of research to understand patients’ perspectives and experiences and via participation in the HTA process. It is challenging for patients to access clinical trials and they face delays in access to new medicines, new HTA processes could mean further delays. There are a range of ways in which healthcare stakeholders could engage with patients and patient groups. Multi-stakeholder forums could be particularly valuable and lead to development of joint solutions that could improve drug development and reduce time to access of patients.
Sponsor: Eli Lilly